Gynecologic Cancer
Conference Coverage
Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer
The novel antibody-drug conjugate tisotumab vedotin (TV) shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic...
Conference Coverage
Brachytherapy access may mediate poor cervical cancer survival in blacks
“This is the first study, to our knowledge, to show such an interaction between race and survival being mediated by one particular treatment...
Conference Coverage
Study explores third-line trabectedin plus PLD for BRCA1/2 ovarian cancer
Adding trabectedin to PLD significantly prolonged OS and PFS in BRCA1/2 patients with advanced epithelial OC, according to a prespecified phase 3...
Conference Coverage
Combo shows promise for endometrial, ovarian cancers
HONOLULU – Combination lenvatinib and paclitaxel produced an objective response rate of 65%, and most adverse events were grade 1 or 2.
Conference Coverage
Study: Racial disparities in gyn-onc trial enrollment persist
HONOLULU – A literature review shows that racial disparities in trial enrollment remain and may be increasing;...
Conference Coverage
ARIEL3 analysis: Rucaparib PFS benefit in recurrent OC occurs across age groups
HONOLULU – The improved PFS seen with maintenance rucaparib vs. placebo in women with recurrent ovarian cancer in...
Conference Coverage
Neratinib shows promise in HER2-mutant cervical cancer
HONOLULU – Treatment leads to durable responses and disease control in heavily pretreated metastatic patients with...
Conference Coverage
Perceived cancer risk may improve access to HPV vaccine
HONOLULU – The perceived risk of HPV-related cancer appears to overcome variables that typically impede access to...
Conference Coverage
WISP: Early data provide further support for ISDO in women at high OC risk
HONOLULU – RRSO or ISDO each lead to significant reductions in cancer distress, but regret is greater with RRSO,...
Conference Coverage
Triplet appears safe, effective for gynecologic cancers
HONOLULU – Tumor response rate was 40% with pembrolizumab plus bevacizumab and oral metronomic cyclophosphamide in patients with recurrent...
Conference Coverage
Combo may improve PFS, OS for certain ovarian cancer patients
HONOLULU - Combining avelumab with pegylated liposomal doxorubicin may provide a survival benefit in certain patients with platinum-resistant or...